Updated on 2024/05/09

写真a

 
MORISE Masahiro
 
Organization
Graduate School of Medicine Program in Integrated Medicine Internal Medicine Lecturer
Undergraduate School
School of Medicine Department of Medicine
Title
Lecturer
Contact information
メールアドレス

Degree 1

  1. 博士(医学) ( 2010.9   名古屋大学 ) 

Research Interests 3

  1. 化学療法に関する支持療法

  2. 悪性胸膜中皮腫

  3. 肺癌

Research History 1

  1. Nagoya University   Nagoya University Hospital   Postgraduate Clinical Training and Career Development Support Center, Deputy Director

    2017.2 - 2019.3

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2010.3

      More details

    Country: Japan

  2. Gifu University   Faculty of Medicine

    - 2000.3

      More details

    Country: Japan

Professional Memberships 6

  1. European Society for Medical Oncology

  2. International Association for The Study Of Lung Cancer

  3. 日本臨床腫瘍学会

  4. 日本呼吸器学会

  5. 日本肺癌学会

  6. 日本内科学会

▼display all

Committee Memberships 3

  1. 日本肺癌学会 ガイドライン検討委員会   薬物療法小委員会 委員  

    2016.12   

  2. 日本肺癌学会 肺癌登録合同委員会   悪性胸膜中皮腫登録事業 委員  

    2016   

  3. 日本肺癌学会 ガイドライン検討委員会   薬物療法および集学的治療小委員会協力委員  

    2014.4 - 2016.12   

 

Papers 91

  1. Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial Invited Reviewed International journal

    Matsuzawa, R; Morise, M; Ito, K; Hataji, O; Takahashi, K; Koyama, J; Kuwatsuka, Y; Imaizumi, K; Goto, Y; Itani, H; Yamaguchi, T; Zenke, Y; Oki, M; Ishii, M

    ECLINICALMEDICINE   Vol. 66   page: 102303   2023.12

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.eclinm.2023.102303

    Web of Science

    PubMed

  2. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC Reviewed International coauthorship International journal

    Herbst Roy S., Giaccone Giuseppe, de Marinis Filippo, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos H., Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Zou Wei, Sandler Alan, Enquist Ida, Komatsubara Kimberly, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, McCleland Mark, Mocci Simonetta, Jassem Jacek, Spigel David R.

    NEW ENGLAND JOURNAL OF MEDICINE   Vol. 383 ( 14 ) page: 1328 - 1339   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1056/NEJMoa1917346

    Web of Science

  3. Long-term experience with tepotinib in Japanese patients with <i>MET</i> exon 14 skipping NSCLC from the Phase II VISION study Reviewed International coauthorship International journal

    Morise, M; Kato, T; Matsumoto, S; Inoue, T; Sakamoto, T; Tokito, T; Atagi, S; Kozuki, T; Takeoka, H; Chikamori, K; Shinagawa, N; Tanaka, H; Horii, E; Adrian, S; Bruns, R; Johne, A; Paik, PK; Sakai, H

    CANCER SCIENCE   Vol. 115 ( 4 ) page: 1296 - 1305   2024.4

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.16107

    Web of Science

    PubMed

  4. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 Reviewed International journal

    Ito, K; Morise, M; Wakuda, K; Hataji, O; Shimokawaji, T; Takahashi, K; Furuya, N; Takeyama, Y; Goto, Y; Abe, T; Kato, T; Ozone, S; Ikeda, S; Kogure, Y; Yokoyama, T; Kimura, M; Yoshioka, H; Murotani, K; Kondo, M; Saka, H

    ESMO OPEN   Vol. 6 ( 3 ) page: 100115   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.esmoop.2021.100115

    Web of Science

    PubMed

  5. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR Reviewed International journal

    Matsuzawa, R; Morise, M; Kinoshita, F; Tanaka, I; Koyama, J; Kimura, T; Kondoh, Y; Tanaka, T; Shima, K; Hase, T; Wakahara, K; Ishii, M; Hashimoto, N

    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY   Vol. 149 ( 7 ) page: 3885 - 3893   2023.7

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00432-022-04300-x

    Web of Science

    PubMed

  6. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung Reviewed

    Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, Ishii G

    Journal of cancer research and clinical oncology     page: 2015 May 12. [Epub ahead of print]   2015

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00432-015-1985-3

  7. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE Reviewed International journal

    Hata, A; Okamoto, I; Inui, N; Okada, M; Morise, M; Akiyoshi, K; Takeda, M; Watanabe, Y; Sugawara, S; Shinagawa, N; Kubota, K; Saeki, T; Tamura, T

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 40 ( 2 ) page: 180 - +   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1200/JCO.21.01315

    Web of Science

    PubMed

  8. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC Reviewed International coauthorship International journal

    Jassem, J; de Marinis, F; Giaccone, G; Vergnenegre, A; Barrios, CH; Morise, M; Felip, E; Oprean, C; Kim, YC; Andric, Z; Mocci, S; Enquist, I; Komatsubara, K; McCleland, M; Kuriki, H; Villalobos, M; Phan, S; Spigel, DR; Herbst, RS

    JOURNAL OF THORACIC ONCOLOGY   Vol. 16 ( 11 ) page: 1872 - 1882   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtho.2021.06.019

    Web of Science

    PubMed

  9. Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis Reviewed

      Vol. 9 ( 9 ) page: 1324-31   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  10. Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Reviewed International journal

    Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y

    Molecular and clinical oncology   Vol. 2 ( 6 ) page: 991 - 996   2014.11

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/mco.2014.354

    PubMed

  11. Nongenomic Effects of Fluticasone Propionate and Budesonide on Human Airway Anion Secretion Reviewed International journal

    Mizutani, T; Morise, M; Ito, Y; Hibino, Y; Matsuno, T; Ito, S; Hashimoto, N; Sato, M; Kondo, M; Imaizumi, K; Hasegawa, Y

    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY   Vol. 47 ( 5 ) page: 645 - 651   2012.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1165/rcmb.2012-0076OC

    Web of Science

    PubMed

  12. Capsaicinoids Regulate Airway Anion Transporters through Rho Kinase- and Cyclic AMP-Dependent Mechanisms Reviewed International journal

    Hibino, Y; Morise, M; Ito, Y; Mizutani, T; Matsuno, T; Ito, S; Hashimoto, N; Sato, M; Kondo, M; Imaizumi, K; Hasegawa, Y

    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY   Vol. 45 ( 4 ) page: 684 - 691   2011.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1165/rcmb.2010-0332OC

    Web of Science

    PubMed

  13. Heterologous regulation of anion transporters by menthol in human airway epithelial cells Reviewed International journal

    Morise, M; Ito, Y; Matsuno, T; Hibino, Y; Mizutani, T; Ito, S; Hashimoto, N; Kondo, M; Imaizumi, K; Hasegawa, Y

    EUROPEAN JOURNAL OF PHARMACOLOGY   Vol. 635 ( 1-3 ) page: 204 - 211   2010.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ejphar.2010.03.032

    Web of Science

    PubMed

  14. BRAFV600E Promotes Anchorage-Independent Growth but Inhibits Anchorage-Dependent Growth in hTERT / Cdk4-Immortalized Normal Human Bronchial Epithelial Cells. Reviewed International coauthorship International journal

    Muraki N, Kawabe N, Ohashi A, Umeda K, Katsuda M, Tomatsu A, Yoshida M, Komeda K, Minna JD, Tanaka I, Morise M, Matsushima M, Matsui Y, Kawabe T, Sato M

    Experimental cell research     page: 114057   2024.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.yexcr.2024.114057

    PubMed

  15. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with <i>MET</i> exon 14 skipping enrolled in VISION Reviewed International coauthorship International journal

    Kato, T; Yang, JCH; Ahn, MJ; Sakai, H; Morise, M; Chen, YM; Han, JY; Yang, JJ; Zhao, J; Hsia, TC; Berghoff, K; Bruns, R; Vioix, H; Lang, S; Johne, A; Le, XN; Paik, PK

    BRITISH JOURNAL OF CANCER     2024.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41416-024-02615-9

    Web of Science

    PubMed

  16. Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report Reviewed International journal

    Kato, S; Sakamoto, K; Sato, T; Kobayashi, T; Shindo, Y; Morise, M; Iwama, S; Arima, H; Ishii, M

    RESPIRATORY INVESTIGATION   Vol. 62 ( 2 ) page: 313 - 316   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.resinv.2024.01.009

    Web of Science

    PubMed

  17. Real-time ultrasound-guided thoracentesis simulation using an optical see-through head-mounted display: a proof-of-concept study Reviewed International journal

    Okachi, S; Matsui, T; Sakurai, M; Ito, T; Morise, M; Imaizumi, K; Ishii, M; Fujiwara, M

    JOURNAL OF ULTRASONOGRAPHY   Vol. 24 ( 96 ) page: 20240012   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.15557/jou.2024.0012

    Web of Science

    PubMed

  18. Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan Reviewed International journal

    Hasegawa, S; Shintani, Y; Takuwa, T; Aoe, K; Kato, K; Fujimoto, N; Hida, Y; Morise, M; Moriya, Y; Morohoshi, T; Suzuki, H; Chida, M; Endo, S; Kadokura, M; Okumura, M; Hattori, S; Date, H; Yoshino, I

    CANCER SCIENCE   Vol. 115 ( 2 ) page: 507 - 528   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.16021

    Web of Science

    PubMed

  19. Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan. Reviewed International journal

    Nogami N, Nakamura A, Shiraiwa N, Kikkawa H, Emir B, Wiltshire R, Morise M

    Future oncology (London, England)   Vol. 19 ( 37 ) page: 2453 - 2463   2023.12

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2217/fon-2023-0109

    PubMed

  20. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase Reviewed International journal

    Inui, N; Toi, Y; Yoneshima, Y; Morise, M; Hata, A; Kubota, K; Saeki, T; Tamura, T

    ADVANCES IN THERAPY   Vol. 40 ( 11 ) page: 4928 - 4944   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12325-023-02648-1

    Web of Science

    PubMed

  21. The Application of Mixed Reality in Bronchoscopy Simulation Training: A Feasibility Study Reviewed International journal

    Okachi, S; Sakurai, M; Matsui, T; Ito, T; Matsuzawa, R; Morise, M; Wakahara, K; Ishii, M; Fujiwara, M

    SURGICAL INNOVATION   Vol. 30 ( 5 ) page: 685 - 686   2023.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1177/15533506231160201

    Web of Science

    PubMed

  22. Two Cases of Latex-allergic Patients with Obtaining Definite Diagnosis of Mediastinal Lymphadenopathy by EBUS-TBNA Without a Balloon Reviewed International journal

    Matsuzawa Reiko, Ito Takayasu, Imaizumi Kazuyoshi, Ishii Azusa, Ito Katsuki, Futamura Keisuke, Okachi Shotaro, Morise Masahiro, Wakahara Keiko, Ishii Makoto

    The Journal of the Japan Society for Respiratory Endoscopy   Vol. 45 ( 5 ) page: 339 - 344   2023.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society for Respiratory Endoscopy  

    <p><b><i>Background.</i></b> Few studies have investigated whether endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can be conducted without a balloon for a definitive diagnosis of mediastinal lymphadenopathy. <b><i>Case 1.</i></b> A woman in her 70s with an allergy to rubber gloves. During an examination for uveitis, CT showed multiple enlarged lymph nodes in #4R and #7. <b><i>Case 2.</i></b> A man in his 40s presented with an allergy to rubber gloves. Follow-up CT after the surgical treatment of lung adenocarcinoma revealed an enlarged lymph node (#7). <b><i>Results.</i></b> EBUS-TBNA was performed in these two cases to definitively diagnose enlarged mediastinal lymph nodes without a balloon. In Case 1, #7 and #4R had short diameters of 10 mm and 15 mm, respectively, while in Case 2, #7 had a short diameter of 17 mm. The lesion was delineated and punctured without a balloon. Case 1 was diagnosed with sarcoidosis, and case 2 was diagnosed with recurrent lung adenocarcinoma. <b><i>Conclusions.</i></b> It is crucial to carefully assess whether the target lesion is puncturable before the examination when performing EBUS-TBNA without a balloon.</p>

    DOI: 10.18907/jjsre.45.5_339

    CiNii Research

  23. Silencing of <i>GRHL2</i> induces epithelial-to-mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth Reviewed International coauthorship International journal

    Kawabe, N; Matsuoka, K; Komeda, K; Muraki, N; Takaba, M; Togami, Y; Ito, Y; Yamada, M; Sunaga, N; Girard, L; Minna, JD; Cai, L; Xie, Y; Tanaka, I; Morise, M; Sato, M

    ONCOLOGY LETTERS   Vol. 26 ( 3 ) page: 391   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3892/ol.2023.13977

    Web of Science

    PubMed

  24. Metabolic barriers in non-small cell lung cancer with <i>LKB1</i> and/or <i>KEAP1</i> mutations for immunotherapeutic strategies Reviewed International journal

    Tanaka, I; Koyama, J; Itoigawa, H; Hayai, S; Morise, M

    FRONTIERS IN ONCOLOGY   Vol. 13   page: 1249237   2023.8

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fonc.2023.1249237

    Web of Science

    PubMed

  25. Usefulness of Transbronchial Needle Aspiration Through a Guide Sheath Using the PeriView FLEX Device in Addition to Endobronchial Ultrasonography with a Guide Sheath Transbronchial Biopsy for the Diagnosis of Pulmonary Actinomycosis Reviewed

    Shinohara Yuka, Ito Takayasu, Okachi Shotaro, Shimoyama Yoshie, Fukutani Eriko, Matsuzawa Reiko, Morise Masahiro, Wakahara Keiko, Ishii Makoto

    The Journal of the Japan Society for Respiratory Endoscopy   Vol. 45 ( 1 ) page: 37 - 42   2023.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society for Respiratory Endoscopy  

    <p><b><i>Background.</i></b> Endobronchial ultrasonography with a guide sheath transbronchial biopsy (EBUS-GS TBB) was shown to be unsatisfactory for the diagnosis of pulmonary actinomycosis. The definitive diagnosis of pulmonary actinomycosis using EBUS-GS often necessitates penetration of the lesion to obtain samples. <b><i>Case.</i></b> A 52-year-old woman was referred to our hospital for the evaluation of an increase in nodules observed on chest computed tomography over 2 years prior to presentation. <b><i>Results.</i></b> A histopathological evaluation of specimens retrieved using EBUS-GS TBB revealed nonspecific findings, such as inflammatory cells. However, specimens retrieved via transbronchial needle aspiration through a guide sheath (GS-TBNA) using the PeriView FLEX device in addition to those obtained via EBUS-GS TBB showed necrotic tissue. Culture of tissue obtained using EBUS-GS TBB yielded <i>Actinomyces odontolyticus</i>. Based on these results, we diagnosed the lesion as pulmonary actinomycosis, and the patient was administered antibiotics, which led to the improvement of the lesion. <b><i>Conclusion.</i></b> GS-TBNA performed in addition to EBUS-GS TBB facilitated direct penetration of the lesion to obtain samples for an accurate diagnosis of pulmonary actinomycosis.</p>

    DOI: 10.18907/jjsre.45.1_37

    CiNii Research

  26. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade Reviewed International journal

    Kobayashi, T; Iwama, S; Yamagami, A; Yasuda, Y; Okuji, T; Ito, M; Zhou, X; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Ito, T; Kikumori, T; Inoue, M; Ando, Y; Masuda, N; Kawashima, H; Hashimoto, N; Arima, H

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 10 ) page: E4115 - E4123   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1210/clinem/dgac467

    Web of Science

    PubMed

  27. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. Reviewed International journal

    Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T

    ESMO open   Vol. 7 ( 4 ) page: 100527   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.esmoop.2022.100527

    PubMed

  28. Clinical efficacy of osimertinib in <i>EGFR</i>-mutant non-small cell lung cancer with distant metastasis Reviewed International journal

    Gen, S; Tanaka, I; Morise, M; Koyama, J; Kodama, Y; Matsui, A; Miyazawa, A; Hase, T; Hibino, Y; Yokoyama, T; Kimura, T; Yoshida, N; Sato, M; Hashimoto, N

    BMC CANCER   Vol. 22 ( 1 ) page: 654   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12885-022-09741-8

    Web of Science

    PubMed

  29. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) Reviewed International journal

    Hata, A; Shiraishi, Y; Inui, N; Okada, M; Morise, M; Akiyoshi, K; Takeda, M; Watanabe, Y; Sugawara, S; Shinagawa, N; Kubota, K; Saeki, T; Tamura, T

    ONCOLOGY AND THERAPY   Vol. 10 ( 1 ) page: 253 - 262   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s40487-022-00188-2

    Web of Science

    PubMed

  30. Resistance to mutant <i>KRAS<sub>V12</sub></i>-induced senescence in an <i>hTERT</i>/<i>Cdk4</i>-immortalized normal human bronchial epithelial cell line Reviewed International coauthorship International journal

    Muraki, N; Yamada, M; Doki, H; Nakai, R; Komeda, K; Goto, D; Kawabe, N; Matsuoka, K; Matsushima, M; Kawabe, T; Tanaka, I; Morise, M; Shay, JWW; Minna, JDD; Sato, M

    EXPERIMENTAL CELL RESEARCH   Vol. 414 ( 1 ) page: 113053   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.yexcr.2022.113053

    Web of Science

    PubMed

  31. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline Reviewed International journal

    Iwama, S; Kobayashi, T; Yasuda, Y; Okuji, T; Ito, M; Ando, M; Zhou, X; Yamagami, A; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Takagi, H; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Wakahara, K; Yokota, K; Kato, M; Nishio, N; Tanaka, C; Miyata, K; Ogura, A; Ito, T; Sawada, T; Shimokata, T; Niimi, K; Ohka, F; Ishigami, M; Gotoh, M; Hashimoto, N; Saito, R; Kiyoi, H; Kajiyama, H; Ando, Y; Hibi, H; Sone, M; Akiyama, M; Kodera, Y; Arima, H

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 4 ) page: E1620 - E1630   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1210/clinem/dgab829

    Web of Science

    PubMed

  32. INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance Reviewed International coauthorship International journal

    Smit Egbert F., Dooms Christophe, Raskin Jo, Nadal Ernest, Tho Lye M., Le Xiuning, Mazieres Julien, Hin How S., Morise Masahire, Zhu Viola W., Tan Daniel, Holmberg Kristina H., Ellers-Lenz Barbara, Adrian Svenja, Brutlach Sabine, Schumacher Karl M., Karachaliou Niki, Wu Yi-Long

    FUTURE ONCOLOGY   Vol. 18 ( 9 ) page: 1039 - 1054   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2217/fon-2021-1406

    Web of Science

  33. Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer A retrospective observational study Reviewed International journal

    Oi, H; Matsuda, T; Kimura, T; Morise, M; Yamano, Y; Yokoyama, T; Kataoka, K; Kondoh, Y

    MEDICINE   Vol. 101 ( 6 ) page: e28863   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/MD.0000000000028863

    Web of Science

    PubMed

  34. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor<i> receptor</i> 2 exon-20 insertion mutations Reviewed International journal

    Iwama, E; Zenke, Y; Sugawara, S; Daga, H; Morise, M; Yanagitani, N; Sakamoto, T; Murakami, H; Kishimoto, J; Matsumoto, S; Nakanishi, Y; Goto, K; Okamoto, I

    EUROPEAN JOURNAL OF CANCER   Vol. 162   page: 99 - 106   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ejca.2021.11.021

    Web of Science

    PubMed

  35. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations Reviewed International journal

    Tanaka, I; Morise, M

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   Vol. 23 ( 1 )   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/ijms23010245

    Web of Science

    PubMed

  36. Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer Reviewed International journal

    Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

    Internal Medicine   Vol. 61 ( 5 ) page: 703 - 708   2022

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    <p>Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a <i>BRAF V600E</i> mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with <i>BRAF V600E</i> mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression. </p>

    DOI: 10.2169/internalmedicine.6657-20

    Web of Science

    PubMed

    CiNii Research

  37. A phase I/II study of osimertinib in <i>EGFR</i> exon 20 insertion mutation-positive non-small cell lung cancer Reviewed International journal

    Yasuda, H; Ichihara, E; Sakakibara-Konishi, J; Zenke, Y; Takeuchi, S; Morise, M; Hotta, K; Sato, M; Matsumoto, S; Tanimoto, A; Matsuzawa, R; Kiura, K; Takashima, Y; Yano, S; Koyama, J; Fukushima, T; Hamamoto, J; Terai, H; Ikemura, S; Takemura, R; Goto, K; Soejima, K

    LUNG CANCER   Vol. 162   page: 140 - 146   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lungcan.2021.10.006

    Web of Science

    PubMed

  38. Is area under the curve the best parameter for carboplatin induced emetic risk stratification? Reviewed International journal

    Ozone, S; Ichikawa, K; Morise, M; Matsui, A; Kinoshita, F; Matsuzawa, R; Koyama, J; Tanaka, I; Hashimoto, N

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 4 ) page: 773 - 785   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18999/nagjms.83.4.773

    Web of Science

    PubMed

  39. Oxytocin receptor is a promising therapeutic target of malignant mesothelioma Reviewed International journal

    Kodama, Y; Tanaka, I; Sato, T; Hori, K; Gen, S; Morise, M; Matsubara, D; Sato, M; Sekido, Y; Hashimoto, N

    CANCER SCIENCE   Vol. 112 ( 9 ) page: 3520 - 3532   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.15025

    Web of Science

    PubMed

  40. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence Reviewed International journal

    Tanaka, I; Furukawa, T; Morise, M

    CANCER CELL INTERNATIONAL   Vol. 21 ( 1 ) page: 454   2021.8

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12935-021-02165-7

    Web of Science

    PubMed

  41. Tepotinib in patients with NSCLC harbouring <i>MET</i> exon 14 skipping: Japanese subset analysis from the Phase II VISION study Reviewed International journal

    Sakai, H; Morise, M; Kato, T; Matsumoto, S; Sakamoto, T; Kumagai, T; Tokito, T; Atagi, S; Kozuki, T; Tanaka, H; Chikamori, K; Shinagawa, N; Takeoka, H; Bruns, R; Straub, J; Schumacher, KM; Paik, PK

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 51 ( 8 ) page: 1261 - 1268   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jjco/hyab072

    Web of Science

    PubMed

  42. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Reviewed International journal

    Nakano, T; Kuribayashi, K; Kondo, M; Morise, M; Tada, Y; Hirano, K; Hayashi, M; Tanaka, M; Hirabayashi, M

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   Vol. 17 ( 3 ) page: 264 - 272   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ajco.13455

    Web of Science

    PubMed

  43. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma Reviewed International journal

    Nakagawa, K; Kijima, T; Okada, M; Morise, M; Kato, M; Hirano, K; Fujimoto, N; Takenoyama, M; Yokouchi, H; Ohe, Y; Hida, T; Aoe, K; Kishimoto, T; Hirokawa, M; Matsuki, H; Kaneko, Y; Yamada, T; Morimoto, C; Takeda, M

    JTO CLINICAL AND RESEARCH REPORTS   Vol. 2 ( 6 ) page: 100178   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtocrr.2021.100178

    Web of Science

    PubMed

  44. Evaluation of reactivity of HISCL<sup>TM</sup> SARS-CoV-2 antibody reagent Reviewed International journal

    KIKUCHI Ryosuke, SUZUKI Atsuo, KIM Jeong Hui, WATARAI Rika, MORISE Masahiro, SAITO Shoji, YAGI Tetsuya, MATSUSHITA Tadashi

    Japanese Journal of Medical Technology   Vol. 70 ( 2 ) page: 220 - 227   2021.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japanese Association of Medical Technologists  

    <p>Antibody detection reagents for the novel coronavirus SARS-CoV-2 can be classified into two types: those that detect antibodies to the spike protein S1 domain (S) and/or the nucleocapsid protein (N) of SARS-CoV-2. In this study, we evaluated the reactivity of the HISCL<sup>TM</sup> SARS-CoV-2 antibody reagent in three cases of COVID-19. In case 1, IgM antibodies were detected when using the HISCL<sup>TM</sup> SARS-CoV-2 S-IgM reagent from the time of admission to the hospital (day X). In case 2, SARS-CoV-2 antibodies were detected when using the HISCL SARS-CoV-2 S-IgM, N-IgM, and N-IgG reagents from the X + 1st day, and IgG antibodies were detected from the X + 2nd day when using the HISCL<sup>TM</sup> SARS-CoV-2 S-IgG reagent . In case 3, positive results were obtained from X + 12th day for the HISCL<sup>TM</sup> SARS-CoV-2 S-IgM and S-IgG reagents. These results suggest that among the HISCL<sup>TM</sup> SARS-CoV-2 reagents, the S-targeting antibody reagent could detect SARS-CoV-2 antibodies earlier than the N-targeting antibody reagent.</p>

    DOI: 10.14932/jamt.20-131

    CiNii Research

  45. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations Reviewed International journal

    Ninomiya, K; Teraoka, S; Zenke, Y; Kenmotsu, H; Nakamura, Y; Okuma, Y; Tamiya, A; Nosaki, K; Morise, M; Aokage, K; Oya, Y; Kozuki, T; Sakamoto, T; Tanaka, K; Tanaka, H; Tanizaki, J; Miura, S; Mizutani, H; Miyauchi, E; Yamaguchi, O; Ebi, N; Goto, Y; Sasaki, T; Daga, H; Morita, S; Yamanaka, T; Amano, S; Hasegawa, K; Imamura, CK; Suzuki, K; Nakajima, K; Nishimoto, H; Oizumi, S; Hida, T; Hotta, K; Takiguchi, Y

    JTO CLINICAL AND RESEARCH REPORTS   Vol. 2 ( 1 ) page: 100107   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtocrr.2020.100107

    Web of Science

    PubMed

  46. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET) Reviewed International journal

    Takeuchi, S; Yanagitani, N; Seto, T; Hattori, Y; Ohashi, K; Morise, M; Matsumoto, S; Yoh, K; Goto, K; Nishio, M; Takahara, S; Kawakami, T; Imai, Y; Yoshimura, K; Tanimoto, A; Nishiyama, A; Murayama, T; Yano, S

    TRANSLATIONAL LUNG CANCER RESEARCH   Vol. 10 ( 1 ) page: 314 - 325   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21037/tlcr-20-549

    Web of Science

    PubMed

  47. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series International journal

    Ishi Azusa, Tanaka Ichidai, Iwama Shintaro, Sakakibara Toshihiro, Mastui Toshinori, Kobayashi Tomoko, Hase Tetsunari, Morise Masahiro, Sato Mitsuo, Arima Hiroshi, Hashimoto Naozumi

    Endocrine Journal   Vol. 68 ( 5 ) page: 613 - 620   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japan Endocrine Society  

    <p>The programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis is vital for immune resistance during tumor development, while PD-L1 inhibitors can also inhibit the PD-L1/B7-1 (CD80) interaction, indicating one of the molecular differences between PD-1 and PD-L1 inhibitors. However, the clinical benefits of PD-L1 inhibitors in patients previously treated with PD-1 inhibitors remain unknown. In this study, we retrospectively analyzed the clinical data of eight patients with non-small cell lung cancer who received the PD-L1 inhibitor atezolizumab and previously treated with the PD-1 inhibitor nivolumab. The median progression-free survival was 2.1 months (1.8–18.7 months), and 4 of 8 patients achieved at least stable disease. In two of these patients, atezolizumab treatment resulted in longer progression-free survival (PFS) compared with that of nivolumab. Conversely, one patient exhibited grade 4 diabetic ketoacidosis (DKA) within 2 weeks after the initial administration of atezolizumab. Another patient had developed type 1 diabetes mellitus (T1DM) during the prior nivolumab treatment and then developed DKA due to an infection after the initiation of atezolizumab. Both of them had high-risk human leukocyte antigen-DR/DQ types relevant to T1DM. These results demonstrate the potential efficacy of PD-L1 inhibitors to some tumors that have acquired resistance to PD-1 inhibitors and suggest that appropriate managements are required for not only a newly onset of T1DM but also blood glucose control after the development of T1DM during a reiteration of the PD-1/PD-L1 blockade.</p>

    DOI: 10.1507/endocrj.EJ20-0769

    Web of Science

    PubMed

    CiNii Research

  48. Comparative study of anti-SARS-CoV-2 antibody testing: Relationship between target antigen and immunoglobulin isotype Reviewed International journal

    KIM Jeong Hui, KIKUCHI Ryosuke, SUZUKI Atsuo, WATARAI Rika, YOKOYAMA Satoru, MORISE Masahiro, YAGI Tetsuya, MATSUSHITA Tadashi

    Japanese Journal of Medical Technology   Vol. 69 ( 4 ) page: 554 - 561   2020.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japanese Association of Medical Technologists  

    <p>As the novel coronavirus disease (COVID-19) pandemic evolves, anti-SARS-CoV-2 antibody (Ab) testing has emerged as an additional or alternative tool for COVID-19 diagnosis. The two antigens used in serological test are the nucleocapsid protein (N) and the spike protein S1 domain (S). In this study, we aimed to validate the performance of seven types of commercial lateral flow immunoassay (LFIA) kits and four types of antibody detection reagents using autoanalyzers as serological testing for COVID-19. Seven types of LFIA kits were purchased from five companies, Kurabo, RayBiotech, Innovita Biological Technology, LumiQuick Diagnostics, and Lepu Medical Technology. Four types of antibody detection reagents were obtained from three companies, Abbot, Roche Diagnostics, and Ortho-Clinical Diagnostics. We tested sequential sera from two patients diagnosed as having COVID-19 by reverse transcription (RT)-quantitative polymerase chain reaction (qPCR). The IgG Ab against the SARS-CoV-2 N protein was detected earlier than IgM Ab, whereas IgM and IgG Ab against the SARS-CoV-2 S protein were detectable from the early stage of infection. These results suggest that S-based Ab detection has a potential for the early detection of SARS-CoV-2 in hospitals, clinics, and test laboratories.</p>

    DOI: 10.14932/jamt.20-71

    CiNii Research

  49. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study Reviewed International coauthorship International journal

    Seto, T; Hayashi, H; Satouchi, M; Goto, Y; Niho, S; Nogami, N; Hida, T; Takahashi, T; Sakakibara-Konishi, J; Morise, M; Nagasawa, T; Suzuki, M; Ohkura, M; Fukuhara, K; Thurm, H; Peltz, G; Nishio, M

    CANCER SCIENCE   Vol. 111 ( 10 ) page: 3726 - 3738   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.14576

    Web of Science

    PubMed

  50. Clinical burden of immune checkpoint inhibitor-induced pneumonitis Reviewed International journal

    Sakamoto, K; Fukihara, J; Morise, M; Hashimoto, N

    RESPIRATORY INVESTIGATION   Vol. 58 ( 5 ) page: 305 - 319   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.resinv.2020.05.008

    Web of Science

    PubMed

  51. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer Reviewed International journal

    Matsui, A; Morise, M; Tanaka, I; Ozone, S; Matsuzawa, R; Koyama, J; Hase, T; Hashimoto, N; Sato, M; Hasegawa, Y

    CANCER INVESTIGATION   Vol. 38 ( 7 ) page: 424 - 430   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/07357907.2020.1793350

    Web of Science

    PubMed

  52. Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With <i>EGFR</i> Mutation Reviewed International journal

    Tanaka, I; Morise, M; Miyazawa, A; Kodama, Y; Tamiya, Y; Gen, S; Matsui, A; Hase, T; Hashimoto, N; Sato, M; Hasegawa, Y

    CLINICAL LUNG CANCER   Vol. 21 ( 3 ) page: 273 - +   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2020.01.011

    Web of Science

    PubMed

  53. Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With NoneSmall-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors" Reviewed International journal

    Fukihara, J; Sakamoto, K; Koyama, J; Ito, T; Iwano, S; Morise, M; Ogawa, M; Kondoh, Y; Kimura, T; Hashimoto, N; Hasegawa, Y

    CLINICAL LUNG CANCER   Vol. 21 ( 3 ) page: E205 - E205   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2019.11.013

    Web of Science

    PubMed

  54. <i>UHRF1</i>, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer Reviewed International journal

    Goto, D; Komeda, K; Uwatoko, N; Nakashima, M; Koike, M; Kawai, K; Kodama, Y; Miyazawa, A; Tanaka, I; Hase, T; Morise, M; Hasegawa, Y; Kawabe, T; Sato, M

    CANCER INVESTIGATION   Vol. 38 ( 4 ) page: 240 - 249   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/07357907.2020.1747483

    Web of Science

    PubMed

  55. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study Reviewed International journal

    Shimokawa, M; Nosaki, K; Seto, T; Ohashi, K; Morise, M; Horinouchi, H; Sakakibara, J; Murakami, H; Yano, S; Satouchi, M; Matsumoto, S; Goto, K; Yoh, K

    TRIALS   Vol. 21 ( 1 ) page: 298   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s13063-020-4221-7

    Web of Science

    PubMed

  56. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study Reviewed International journal

    Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    BRITISH JOURNAL OF CANCER   Vol. 122 ( 6 ) page: 771 - 777   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41416-020-0736-7

    Web of Science

  57. Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer Reviewed International journal

    Shimizu, T; Okachi, S; Imai, N; Hase, T; Morise, M; Hashimoto, N; Sato, M; Hasegawa, Y

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 1 ) page: 69 - 77   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18999/nagjms.82.1.69

    Web of Science

    PubMed

  58. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in <i>ALK</i>-positive non-small-cell lung cancer Reviewed International journal

    Nakagawa, K; Hida, T; Nokihara, H; Morise, M; Azuma, K; Kim, YH; Seto, T; Takiguchi, Y; Nishio, M; Yoshioka, H; Kumagai, T; Hotta, K; Watanabe, S; Goto, K; Satouchi, M; Kozuki, T; Koyama, R; Mitsudomi, T; Yamamoto, N; Asakawa, T; Hayashi, M; Hasegawa, W; Tamura, T

    LUNG CANCER   Vol. 139   page: 195 - 199   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lungcan.2019.11.025

    Web of Science

    PubMed

  59. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study Reviewed International journal

    Kobayashi, T; Iwama, S; Yasuda, Y; Okada, N; Okuji, T; Ito, M; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Yokota, K; Hase, T; Morise, M; Hashimoto, N; Ando, M; Fujimoto, Y; Hibi, H; Sone, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

    JOURNAL FOR IMMUNOTHERAPY OF CANCER   Vol. 8 ( 2 )   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/jitc-2020-000779

    Web of Science

    PubMed

  60. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Reviewed International journal

    Sugawara, S; Inui, N; Kanehara, M; Morise, M; Yoshimori, K; Kumagai, T; Fukui, T; Minato, K; Iwashima, A; Takeda, Y; Kubota, K; Saeki, T; Tamura, T

    CANCER   Vol. 125 ( 22 ) page: 4076 - 4083   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cncr.32429

    Web of Science

    PubMed

  61. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors Reviewed International journal

    Fukihara, J; Sakamoto, K; Koyama, J; Ito, T; Iwano, S; Morise, M; Ogawa, M; Kondoh, Y; Kimura, T; Hashimoto, N; Hasegawa, Y

    CLINICAL LUNG CANCER   Vol. 20 ( 6 ) page: 442 - +   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cllc.2019.07.006

    Web of Science

    PubMed

  62. UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer Reviewed International journal

    Goto, D; Kizuki, M; Uwatoko, N; Kawai, K; Koike, M; Nakashima, M; Miyazawa, A; Tanaka, I; Hase, T; Morise, M; Hasegawa, Y; Minna, J; Sato, M

    JOURNAL OF THORACIC ONCOLOGY   Vol. 14 ( 10 ) page: S692 - S692   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtho.2019.08.1470

    Web of Science

  63. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Reviewed International journal

    Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N

    International journal of clinical oncology   Vol. 24 ( 7 ) page: 731 - 770   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-019-01431-z

    Web of Science

    PubMed

  64. Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study Reviewed International journal

    Shimokawa, M; Nosaki, K; Seto, T; Ohashi, K; Morise, M; Fujiwara, Y; Sakakibara, J; Murakami, H; Yano, S; Satouchi, M; Matsumoto, S; Goto, K; Yoh, K

    ANNALS OF ONCOLOGY   Vol. 30   2019.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  65. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations Reviewed International journal

    Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    LUNG CANCER   Vol. 127   page: 169 - 171   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lungcan.2018.11.018

    Web of Science

    PubMed

  66. The Subunit eIF2 ß of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer Reviewed International journal

    Sato, M; Tanaka, I; Goto, D; Kato, T; Kakumu, T; Miyazawa, A; Yogo, N; Hase, T; Morise, M; Sekido, Y; Kondo, M; Hasegawa, Y

    CANCER SCIENCE   Vol. 109   page: 1181 - 1181   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  67. eIF2 beta, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer Reviewed International coauthorship International journal

    Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE   Vol. 109 ( 6 ) page: 1843 - 1852   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13602

    Web of Science

    PubMed

  68. Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer Reviewed International journal

    Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori

    EUROPEAN GERIATRIC MEDICINE   Vol. 9 ( 2 ) page: 255 - 262   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s41999-018-0033-7

    Web of Science

    PubMed

  69. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Reviewed International journal

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL OF THE ENDOCRINE SOCIETY   Vol. 2 ( 3 ) page: 241 - 251   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1210/js.2017-00432

    Web of Science

    PubMed

  70. Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study Reviewed International journal

    Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro

    JOURNAL OF THORACIC DISEASE   Vol. 10 ( 3 ) page: 1968 - 1971   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21037/jtd.2018.03.53

    Web of Science

    PubMed

  71. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting Reviewed International journal

    Tanaka, I; Kawada, K; Morise, M; Hase, T; Hayashi, H; Sokai, A; Fukatsu, A; Kondo, M; Nomura, F; Hasegawa, Y

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 81 ( 2 ) page: 339 - 345   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cancer Chemotherapy and Pharmacology  

    DOI: 10.1007/s00280-017-3497-0

    Web of Science

    Scopus

    PubMed

  72. An <i>EGFR</i>-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib Reviewed International journal

    Sato Mitsuo, Matsui Akira, Shimoyama Yoshie, Omote Norihito, Morise Masahiro, Hase Tetsunari, Tanaka Ichidai, Suzuki Kojiro, Hasegawa Yoshinori

    Internal Medicine   Vol. 57 ( 23 ) page: 3429 - 3432   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    <p>Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (<i>EGFR</i>-TKIs), gefitinib or erlotinib, in <i>EGFR</i>-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an <i>EGFR</i>-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible <i>EGFR</i>-TKI. We suggest that afatinib can be considered as a treatment option for <i>EGFR</i>-mutated tumor undergoing SCC transformation, particularly in the absence of a <i>T790M</i> mutation. </p>

    DOI: 10.2169/internalmedicine.0999-18

    Web of Science

    PubMed

    CiNii Research

  73. Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer Reviewed International journal

    Fukihara, J; Sakamoto, K; Iwano, S; Morise, M; Hashimoto, N; Hasegawa, Y

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   Vol. 197   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  74. 12. Clinical Practice of Lung Cancer in Elderly Patients International journal

    Hasegawa Yoshinori, Morise Masahiro

    Nihon Naika Gakkai Zasshi   Vol. 106 ( 9 ) page: 1986 - 1990   2017.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    DOI: 10.2169/naika.106.1986

    CiNii Research

  75. Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer Reviewed International coauthorship International journal

    Kakumu Tomohiko, Sato Mitsuo, Goto Daiki, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Fukui Takayuki, Yokoi Kohei, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE   Vol. 108 ( 4 ) page: 732 - 743   2017.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13185

    Web of Science

  76. Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung Reviewed International journal

    Morise, M; Hishida, T; Takahashi, A; Yoshida, J; Ohe, Y; Nagai, K; Ishii, G

    JOURNAL OF THORACIC ONCOLOGY   Vol. 12 ( 1 ) page: S719 - S719   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtho.2016.11.949

    Web of Science

  77. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy Reviewed International journal

    Omote, N; Hashimoto, N; Morise, M; Sakamoto, K; Miyazaki, S; Ando, A; Nakahara, Y; Hasegawa, Y

    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE   Vol. 12   page: 3541 - 3547   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2147/COPD.S149456

    Web of Science

    PubMed

  78. Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? Reviewed International journal

    Kato, T; Morise, M; Ando, M; Kojima, E; Ogasawara, T; Suzuki, R; Shindoh, J; Matsumoto, M; Sugino, Y; Ogawa, M; Nozaki, Y; Hase, T; Kondo, M; Saito, H; Hasegawa, Y

    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY   Vol. 142 ( 7 ) page: 1629 - 1640   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00432-016-2170-z

    Web of Science

    PubMed

  79. The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung Reviewed

    Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, Kojima M, Ochiai A, Funai K, Aokage K, Yoshida J, Tsuboi M, Ishii G

    J Cancer Res Clin Oncol   Vol. 142 ( 5 ) page: 905-912   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  80. Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer Reviewed International journal

    Okachi Shotaro, Imai Naoyuki, Imaizumi Kazuyoshi, Iwano Shingo, Ando Masahiko, Hase Tetsunari, Aso Hiromichi, Morise Masahiro, Wakahara Keiko, Ito Satoru, Hashimoto Naozumi, Sato Mitsuo, Kondo Masashi, Hasegawa Yoshinori

    Internal Medicine   Vol. 55 ( 13 ) page: 1705 - 1712   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    <b>Objective </b>Endobronchial ultrasonography with a guide sheath (EBUS-GS) and virtual bronchoscopic navigation (VBN) improves the diagnostic yield in patients with peripheral pulmonary lesions (PPLs). Most previous reports on EBUS-GS-guided transbronchial biopsy (TBB) have included patients with benign and malignant diseases. We aimed to determine the factors that predicted a successful diagnosis by EBUS-GS-guided TBB diagnostic in patients with small peripheral lung cancer, with a focus on the high-resolution computed tomography (HRCT) findings before bronchoscopy. <b>Methods </b>We retrospectively reviewed the medical records of 173 consecutive patients with 175 small (≤30 mm) PPLs who were diagnosed with primary lung cancer between June 2010 and October 2013 at Nagoya University Hospital. All patients underwent EBUS-GS-guided TBB with VBN using a ZioStation computer workstation (Ziosoft, Osaka, Japan). We analyzed the patient characteristics, HRCT findings, diagnostic yield, and the diagnostic factors in small peripheral lung carcinoma. <b>Results </b>The EBUS probe position was within the PPL in 83 of the 175 lesions (47%) and 112 (64.0%) cases were successfully diagnosed by EBUS-GS-guided TBB. A univariate analysis revealed that the following factors were associated with a significantly higher diagnostic yield: CT bronchus sign positivity, a lesion of >20 mm in diameter, a solid nodule, and a probe position that was within the lesion. The following factors were not significant: the lesion location, the number of biopsies, and the lung cancer histology. A multivariate analysis revealed that the following factors significantly affected the diagnostic yield: CT bronchus sign positivity [odds ratio (OR) =2.479]; a probe position that was within the lesion (OR=2.542); and a solid nodule (OR=2.304). <b>Conclusion </b>The significant factors that were significantly associated with a successful diagnosis using EBUS-GS-guided TBB in small peripheral lung carcinoma were as follows: CT bronchus sign positivity, a solid nodule, and a probe position that was within the lesion.

    DOI: 10.2169/internalmedicine.55.6341

    Web of Science

    PubMed

    CiNii Research

  81. Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung Reviewed

    Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A, Ohe Y

    J Cancer Res Clin Oncol   Vol. 141 ( 8 ) page: 1417-25.   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  82. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy Reviewed

    Koriyama H, Ishii G, Yoh K, Neri S, Morise M, Umemura S, Matsumoto S, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A

    J Cancer Res Clin Oncol   Vol. 141 ( 7 ) page: 1163-70   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  83. Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma Reviewed

    Aramaki N, Ishii G, Yamada E, Morise M, Aokage K, Kojima M, Hishida T, Yoshida J, Ikeda N, Tsuboi M, Ochiai A

      Vol. 142 ( 1 ) page: 37-46   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  84. Environmental Factors of Thoracic Malignancies Invited

      Vol. 62 ( 10 ) page: 963 - 968   2014.10

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.11477/mf.1404200014

    CiNii Research

  85. 最新がん薬物療法学 小細胞肺癌 Invited

    森瀬昌宏, 後藤功一

    日本臨床 増刊号   Vol. 72 ( 2 ) page: 346-349   2014

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  86. Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer Reviewed

    Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y

    Jpn J Clin Oncol   Vol. 44 ( 9 ) page: 846-51   2014

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  87. 特集 オンコロジーエマージェンシーと支持療法の進歩 抗がん剤による過敏反応,インフュージョンリアクション Invited

    森瀬昌宏, 後藤功一

    呼吸器内科   Vol. 23   page: 261-267   2013

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  88. 講座 肺癌化学療法の最前線 小細胞肺癌に対する化学療法 Invited

    森瀬昌宏, 後藤功一

    呼吸   Vol. 32 ( 7 ) page: 631-637   2013

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  89. Dual pathway activated by tert-butyl hydroperoxide in human airway anion secretion Reviewed

    Matsuno T, Ito Y, Ohashi T, Morise M, Takeda N, Shimokata K, Imaizumi K, Kume H, Hasegawa Y

    J Pharmacol Exp Ther   Vol. 327 ( 2 ) page: 453-64   2008

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  90. 肺病変を伴ったmulticentiric Castleman’s diseaseの一例 Reviewed

    森瀬昌宏, 下元博史, 本多 豊大, 森 良雄

    日本呼吸器学会誌   Vol. 41   page: 59-65   2003

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  91. 胸壁原発悪性線維性組織球腫の1例 Reviewed

    下元博史, 森瀬昌宏, 佐藤榮作, 山内晶司

    日本胸部臨床   Vol. 62 ( 6 ) page: 561 -566   2003

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

Books 8

  1. 肺癌診療ガイドライン 2018年版.

    日本肺癌学会ガイドライン委員会 ガイドライン委員( Role: Joint editor)

    金原出版  2018 

     More details

    Language:Japanese Book type:Scholarly book

  2. 肺癌診療ガイドライン 2017年版. IV期非小細胞肺癌薬物療法.

    日本肺癌学会ガイドライン委員会( Role: Joint editor)

    金原出版  2017 

     More details

    Language:Japanese Book type:Scholarly book

  3. EBMの手法による肺癌診療ガイドライン 2016年版

    日本肺癌学会 ガイドライン委員会( Role: Contributor)

    金原出版  2016 

     More details

    Language:Japanese

  4. 胸部X線読影セミナー 第7回 日本医事新報

    森瀬昌宏, 大松広伸, 大江裕一郎( Role: Joint author)

    日本医事新報社  2013 

     More details

    Language:Japanese

  5. 小細胞肺癌に用いる抗がん剤の副作用;予測と対策

    佐藤光夫, 森瀬昌宏, 長谷川好規( Role: Joint author)

    へるす出版  2012 

     More details

    Language:Japanese

  6. レジメン別看護速習覚え書き 肺癌

    森瀬昌宏, 大江裕一郎( Role: Joint author)

    メディカ出版  2012 

     More details

    Language:Japanese

  7. 症例から学ぶメディカルオンコロジー 局所進行非小細胞肺癌症例

    森瀬昌宏、長谷川好規( Role: Sole author)

    医薬ジャーナル社  2011.10 

     More details

    Language:Japanese

  8. コリンズスターン 胸部画像診断エッセンシャル 9章 胸膜、胸壁、横隔膜 訳

    森瀬昌宏, 下方智也( Role: Joint author)

    西村書店  2011.4 

     More details

    Language:Japanese

▼display all

Presentations 84

  1. 非小細胞肺癌における免疫チェックポイント阻害剤と細胞障害性抗癌薬との併用 Invited

    森瀬昌宏

    第60回日本呼吸器学会学術講演会  2020.9  一般社団法人日本呼吸器学会

     More details

    Event date: 2020.9

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  2. 肺癌に対する免疫療法の近未来的展望 放射線治療との併用 Invited

    森瀬昌宏

    第59回日本呼吸器学会学術講演会 

     More details

    Event date: 2019.4

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    Country:Japan  

  3. 小細胞肺癌をはじめとする肺神経内分泌腫瘍に対する治療~肺癌診療ガイドラインにおける治療推奨を踏まえて Invited

    森瀬昌宏

    第61回日本肺癌学会学術講演会  2020.11.25  特定非営利法人 日本肺癌学会

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  4. Does the histological differentiation of NSCLC affect the efficacy of immune checkpoint inhibitors?

    Masahiro Morise, Sho Hori, Reiko Matsuzawa, Junji Koyama, Sachiko Ozone, Ichidai Tanaka, Tetsunari Hase, Koji Sakamoto, Shuichi Asano, Yasuhiro Kondoh, Naozumi Hashimoto

    2020.11.26 

     More details

    Event date: 2020.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  5. The indication of primary prevention for febrile neutropenia (FN) in elderly NSCLC patients treated with docetaxel. International conference

    Morise M, Kondo M, Hasegawa Y.

    2016 the Japanese Society of Medical Oncology Annual Meeting 

     More details

    Event date: 2016.7

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  6. The efficacy and safety of re-challenge platinum plus pemtrexed combination therapy for recurrent malignant pleural mesothelioma International conference

    Mariko Morishita, Masahiro Morise, Tetsunari Hase, Mitsuo Sato, Masashi Kondoh, Yoshinori Hasegawa.

    16th World Conference on Lung Cancer 

     More details

    Event date: 2015.9

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  7. Clinicopathological analysis of SRE in patients with SCLC and NSCLC International conference

    Morise M, Kondo M, Hasegawa Y

    Japan Society of Medical Oncology Annual meeting 2015 

     More details

    Event date: 2015.7

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  8. The prophylactic antiemetic treatment failure in patients with lung cancer treated with CBDCA based-chemotherapy International conference

    Ichikawa K, Morise M, Miyazaki M, Hase T, Kondo M, Hasegawa Y, Yamada K

    Japan Society of Medical Oncology Annual meeting 2015 

     More details

    Event date: 2015.7

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

  9. Can we predict serious adverse events (SAEs) and clarify unfit population for platinum-based chemotherapy in elderly patients (over 70 years of age) with advanced Non-small cell lung cancer (NSCLC)? (CJLSG 1203 trial) International conference

    Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindo J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y.

    European Society of Medical Oncology Annual meeting 2014 

     More details

    Event date: 2014.9

    Language:English   Presentation type:Poster presentation  

    Country:Spain  

  10. Clinicopathological analysis of long-term (more than 2 years) progression-free survivors treated with epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive non-small cell lung cancer. International conference

    Masahiro Morise, Koichi Goto, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Kanji Nagai, Yuichiro Ohe.

    15th World Conference on Lung Cancer 

     More details

    Event date: 2013.10

    Language:English   Presentation type:Poster presentation  

    Country:Australia  

  11. Final results of EGFR mutation reanalysis and KRAS mutation screening by Scorpion ARMS method: Phase II Study of Erlotinib for EGFR wild type Non-small cell Lung Cancer Patients. Central Japan Lung Study Group (CJLSG) 0903 trial. International conference

    Eiichi Maruyama, Masahiro Morise, Tetsunari Hase, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Kenji Ogawa, Takuya Ikeda, Yasuhiro Nozaki, Masahiko Ando, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

    15th World Conference on Lung Cancer 

     More details

    Event date: 2013.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Australia  

  12. Phase II Study of Erlotinib for previously treated Non-small-cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation: Central Japan Lung Study Group (CJLSG) 0903 trial International conference

    Masahiro Morise, Hiroyuki Taniguchi, Hideo Saka, Joe Shindoh, Ryujiro Suzuki, Eiji Kojima, Tetsunari Hase, Masashi Kondo, Hiroshi Saito, Yoshinori Hasegawa.

     More details

    Event date: 2012.9

    Language:English   Presentation type:Poster presentation  

    Country:Austria  

  13. 高齢者非小細胞肺癌に対するプラチナ製剤併用療法に関する多施設共同後向き観察研究 (Central Japan Lung Study Group 1203試験)

    田中健太郎、森瀬昌宏、安藤昌彦、加藤俊夫、小島英嗣、小笠原智彦、鈴木隆二郎、進藤丈、松本政実、杉野安輝、野﨑裕広、小川雅弘、長谷哲成、近藤征史、斉藤博、長谷川好規

    第55回日本呼吸器学会学術講演会 

     More details

    Event date: 2015.4

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  14. 再発小細胞肺癌に対しアムルビシン単剤療法を施行した患者の予後因子の検討

    森瀬昌宏, 麻生裕紀, 長谷哲成, 若原恵子, 伊藤理, 橋本直純, 佐藤光夫, 近藤征史, 長谷川好規

    第52回日本癌治療学会総会 

     More details

    Event date: 2014.8

    Language:Japanese   Presentation type:Poster presentation  

    Venue:横浜   Country:Japan  

  15. EGFR-TKIにより2年以上の長期無増悪生存が得られるEGFR遺伝子変異陽性非小細胞肺癌の臨床病理学的検討

    森瀬昌宏、後藤功一、梅村茂樹、松本慎吾、葉清隆、仁保誠治、大松広伸、永井完治、大江裕一郎

    第54回日本肺癌学会総会 

     More details

    Event date: 2013.11

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京   Country:Japan  

  16. Capsaicinoids regulate airway anion transporters through Rho kinase- and cAMP-dependent mechanisms

     More details

    Event date: 2013.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  17. 再発小細胞肺癌に対する60mg/m2・3週投与1週休薬法によるイリノテカン単剤療法の検討 International conference

    森瀬昌宏、仁保誠治、梅村茂樹、松本慎吾、葉清隆、後藤功一、大松広伸、大江裕一郎

    第53回日本肺癌学会総会 

     More details

    Event date: 2012.10

    Language:English   Presentation type:Oral presentation (general)  

    Venue:岡山   Country:Japan  

  18. Prognostic Factors in Recurrent Small Cell Lung Carcinoma International conference

    Masahiro Morise, Takefumi Mizutani, Tomoyo Oguri, Naoyuki Imai, Tetsunari Hase, Yuichiro Shindo, Yoshihiro Inukai, Satoru Ito, Naozumi Hashimoto, Mitsuo Sato, Masashi Kondo, Yoshinori Hasegawa.

    Japan Society of Medical Oncology Annual meeting 

     More details

    Event date: 2012.7

    Language:English   Presentation type:Poster presentation  

    Country:Japan  

  19. Prospective Analysis of Efficacy and Safety of Individualized Administration of Midazolam for Sedation During Bronchoscopy International conference

    Imaizumi K, Hashimoto I, Shindo Y, Imai N, Ogawa T, Morise M, Ito S, Hashimoto N, Sato M, Kondo M, Hasegawa Y

    CHEST 2011 

     More details

    Event date: 2011.10

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  20. ヒト気道上皮のイオン輸送体に対するmentholの細胞骨格を介した制御 International conference

    森瀬昌宏、伊藤康、日比野佳孝、伊藤理、橋本直純、近藤征史、今泉和良、長谷川好規

    アレルギー学会総会秋季大会 

     More details

    Event date: 2010.10

    Language:Japanese   Presentation type:Poster presentation  

    Venue:東京   Country:Japan  

  21. Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs International conference

    Yamaguchi, T; Matsuzawa, R; Morise, M; Ito, K; Hataji, O; Takahashi, K; Koyama, J; Kuwatsuka, Y; Goto, Y; Imaizumi, K; Itani, H; Zenke, Y; Oki, M; Ishii, M

    ANNALS OF ONCOLOGY  2023.11 

     More details

    Event date: 2023.11

    Language:English   Presentation type:Poster presentation  

    DOI: 10.1016/j.annonc.2023.10.612

  22. Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study International conference

    Matsuzawa, R; Morise, M; Ito, K; Hataji, O; Takahashi, K; Kuwatsuka, Y; Goto, Y; Imaizumi, K; Itani, H; Yamaguchi, T; Zenke, Y; Oki, M; Ishii, M

    JOURNAL OF THORACIC ONCOLOGY  2023.4 

     More details

    Event date: 2023.4

    Language:English   Presentation type:Poster presentation  

  23. CLIP1-LTK: a novel target in non-small cell lung cancer International conference

    Izumi, H; Matsumoto, S; Mori, S; Hayashi, K; Watanabe, K; Fukuhara, T; Shibata, Y; Yoh, K; Morise, M; Toyozawa, R; Chikamori, K; Miyamoto, S; Asano, S; Shingyoji, M; Nakao, M; Azuma, K; Niho, S; Ishii, G; Kobayashi, SS; Goto, K

    ANNALS OF ONCOLOGY  2022.7 

     More details

    Event date: 2022.7

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

    DOI: 10.1016/j.annonc.2022.05.062

  24. Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping. International coauthorship International conference

    Kato, T; Yang, JCH; Ahn, MJ; Sakai, H; Morise, M; Chen, YM; Han, JY; Yang, JJ; Zhao, J; Huang, J; Berghoff, K; Bruns, R; Vioix, H; Otto, G; Le, X; Paik, PK

    JOURNAL OF CLINICAL ONCOLOGY  2022.6.1 

     More details

    Event date: 2022.6

    Language:English   Presentation type:Oral presentation (general)  

  25. Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC International conference

    Matsuzawa, R; Morise, M; Ito, K; Hataji, O; Takahashi, K; Hara, T; Goto, Y; Imaizumi, K; Itani, H; Yamaguchi, T; Zenke, Y; Oki, M; Kogure, Y; Hashimoto, N

    JOURNAL OF THORACIC ONCOLOGY  2021.10 

     More details

    Event date: 2021.10

    Language:English   Presentation type:Poster presentation  

  26. Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion-Positive NSCLC International conference

    Kawasumi, K; Morise, M; Kirita, K; Saeki, K; Kameoka, H; Daga, H; Miyazaki, M; Toyozawa, R; Uoi, M; Harada, M; Tamaki, S; Takeda, M; Fujiwara, K; Yamanaka, T; Goto, K

    JOURNAL OF THORACIC ONCOLOGY  2021.10 

     More details

    Event date: 2021.10

    Language:English   Presentation type:Oral presentation (general)  

  27. Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial International coauthorship International conference

    Morise, M; Sakai, H; Veillon, R; Le, XN; Felip, E; Garassino, MC; Cortot, AB; Smit, E; Park, K; Griesinger, F; Britschgi, C; Wu, YL; Berghoff, K; Otto, G; Bruns, R; Paik, P

    ANNALS OF ONCOLOGY  2021.7 

     More details

    Event date: 2021.7

    Language:English   Presentation type:Oral presentation (general)  

    DOI: 10.1016/j.annonc.2021.05.541

  28. Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer International conference

    Oi, H; Yamano, Y; Yokoyama, T; Matsuda, T; Morise, M; Kataoka, K; Kimura, T; Kondoh, Y

    ANNALS OF ONCOLOGY  2019.11 

     More details

    Event date: 2019.11

    Language:English   Presentation type:Poster presentation  

  29. Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC International conference

    Matsuzawa, R; Morise, M; Tanaka, I; Koyama, J; Kimura, T; Kondoh, Y; Hase, T; Sakamoto, K; Hashimoto, N; Hasegawa, Y

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Event date: 2019.10

    Language:English   Presentation type:Poster presentation  

    DOI: 10.1016/j.jtho.2019.08.1526

  30. A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan) International conference

    Daga, H; Umemura, S; Ohe, Y; Shiota, T; Fujita, M; Furuya, N; Tsuda, T; Morise, M; Matsumoto, S; Goto, K

    ANNALS OF ONCOLOGY  2017.10 

     More details

    Event date: 2017.10

    Language:English   Presentation type:Oral presentation (general)  

  31. Comparison of the incidence of skeletal related events (SREs) between non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) International conference

    Morise, M; Kondo, M; Hasegawa, Y

    ANNALS OF ONCOLOGY  2015.12 

     More details

    Event date: 2015.12

    Language:English   Presentation type:Poster presentation  

  32. The Efficacy and Safety of Re-Challenge Platinum plus Pemetrexed Combination Therapy for Recurrent Malignant Pleural Mesothelioma International conference

    Morishita, M; Morise, M; Hase, T; Sato, M; Kondoh, M; Hasegawa, Y

    JOURNAL OF THORACIC ONCOLOGY  2015.9 

     More details

    Event date: 2015.9

    Language:English   Presentation type:Poster presentation  

  33. PHASE II STUDY OF ERLOTINIB FOR PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0903 TRIAL International conference

    Morise, M; Taniguchi, H; Saka, H; Shindoh, J; Suzuki, R; Kojima, E; Hase, T; Kondo, M; Saito, H; Hasegawa, Y

    ANNALS OF ONCOLOGY  2012.9 

     More details

    Event date: 2012.9

    Language:English   Presentation type:Poster presentation  

  34. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC International coauthorship International conference

    Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z. G., Geater S., Ozguroglu M., Mocci S., McCleland M., Enquist I., Komatsubara K. M., Deng Y., Kuriki H., Wen X., Jassem J., Herbst R. S.

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  35. 外来肺癌治療の現状と課題 Invited

    森瀬 昌宏

    日本呼吸ケア・リハビリテーション学会誌  2018.10.15  一般社団法人 日本呼吸ケア・リハビリテーション学会

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    DOI: 10.15032/jsrcr.28.supplement_131s-2

    CiNii Research

  36. P12-2 高齢者におけるEBUS-TBNAの検討(EBUS3,ポスター12,第35回日本呼吸器内視鏡学会学術集会)

    岡地 祥太郎, 今井 直幸, 伊藤 亮太, 小林 大介, 木村 元宏, 村田 直彦, 深津 明日樹, 高嶋 浩司, 梶川 茂久, 丸山 英一, 麻生 裕紀, 進藤 有一郎, 青山 大輔, 森瀬 昌宏, 佐藤 光夫, 近藤 征史, 長谷川 好規, 橋本 泉, 今泉 和良

    気管支学  2012  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.34.special_s218_2

    CiNii Research

  37. P11-4 当院でEBUS-TBNAを施行し,偽陰性診断であった5症例の検討(EBUS2,ポスター11,第35回日本呼吸器内視鏡学会学術集会)

    麻生 裕紀, 今井 直幸, 橋本 泉, 今泉 和良, 魚津 桜子, 田中 一大, 青山 大輔, 伊藤 亮太, 小林 大介, 村田 直彦, 高嶋 浩司, 岡地 祥太郎, 丸山 英一, 深津 明日樹, 木村 元宏, 梶川 茂久, 進藤 有一郎, 森瀬 昌宏, 犬飼 朗博, 佐藤 光夫, 近藤 征史, 長谷川 好規

    気管支学  2012  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.34.special_s217_1

    CiNii Research

  38. P10-5 超音波気管支鏡(EBUS-TBNA)で診断した肺過誤腫の一例(EBUS1,ポスター10,第35回日本呼吸器内視鏡学会学術集会)

    梶川 茂久, 今井 直幸, 麻生 裕紀, 伊藤 亮太, 犬飼 朗博, 青山 大輔, 岡地 祥太郎, 木村 元宏, 小林 大介, 近藤 征史, 佐藤 光夫, 進藤 有一郎, 深津 明日樹, 丸山 英一, 村田 直彦, 森瀬 昌宏, 高嶋 浩司, 橋本 泉, 今泉 和良, 長谷川 好規

    気管支学  2012  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.34.special_s215_2

    CiNii Research

  39. P-346 Capsaicinoids regulate airway anion transporters through Rho kinase- and cAMP-dependent mechanisms

    Japanese Journal of Allergology  2013  Japanese Society of Allergology

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.15036/arerugi.62.473_2

    CiNii Research

  40. P10-3 悪性腫瘍との鑑別を要し, EBUS-TBNA施行した縦隔内副甲状腺嚢胞の一例(EBUS1,ポスター10,第35回日本呼吸器内視鏡学会学術集会)

    高嶋 浩司, 今井 直幸, 伊藤 亮太, 小林 大介, 村田 直彦, 深津 明日樹, 梶川 茂久, 岡地 祥太郎, 丸山 英一, 麻生 裕紀, 青山 大輔, 森瀬 昌宏, 進藤 有一郎, 橋本 泉, 犬飼 朗博, 橋本 直純, 佐藤 光夫, 近藤 征史, 今泉 和良, 長谷川 好規

    気管支学  2012  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.34.special_s214_3

    CiNii Research

  41. 6.EBUS-TBNAが診断に有用であった子宮頸癌肺転移の1例(第40回 日本呼吸器内視鏡学会中部支部会)

    橋本 泉, 今井 直幸, 犬飼 朗博, 岩木 舞, 下方 智也, 森瀬 昌宏, 小川 知美, 山下 良, 田中 一大, 橋本 直純, 佐藤 光夫, 近藤 征史, 今泉 和良, 長谷川 好規

    気管支学  2011  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.33.1_64_6

    CiNii Research

  42. Real-world evidence of crizotinib for ROS1-tested patients with non-small cell lung cancer in Japan International conference

    Morise, M

    ANNALS OF ONCOLOGY  2022.7 

     More details

    Event date: 2022.7

    Language:English   Presentation type:Oral presentation (general)  

    DOI: 10.1016/j.annonc.2022.05.271

  43. PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201). International conference

    Hase, T; Yanagisawa, K; Fukatsu, A; Kimura, T; Kojima, E; Abe, T; Imaizumi, K; Horio, Y; Oguri, T; Yamamoto, M; Ogasawara, T; Sugino, Y; Morise, M; Nakatochi, M; Ando, M; Kondo, M; Saka, H; Saito, H; Hasegawa, Y; Takahashi, T

    JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

     More details

    Event date: 2020.5

    Language:English   Presentation type:Poster presentation  

  44. Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT International conference

    Tamiya, Y; Morise, M; Matsuzawa, R; Tanaka, I; Okada, T; Iwano, S; Hase, T; Hashimoto, N; Sato, M; Itoh, Y; Hasegawa, Y

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Event date: 2019.10

    Language:English   Presentation type:Poster presentation  

    DOI: 10.1016/j.jtho.2019.08.1972

  45. Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

    Yanagitani, N; Takeuchi, S; Murayama, T; Yoshimura, K; Imai, Y; Takahara, S; Kawakami, T; Seto, T; Hattori, Y; Ohashi, K; Morise, M; Matsumoto, S; Yoh, K; Goto, K; Nishio, M; Yano, S

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Event date: 2019.10

    Language:English   Presentation type:Poster presentation  

    DOI: 10.1016/j.jtho.2019.08.411

  46. Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status International conference

    Koyama, J; Kimura, T; Oi, H; Yamano, Y; Yokoyama, T; Matsuda, T; Kataoka, K; Matsuzawa, R; Fukihara, J; Sakamoto, K; Morise, M; Hashimoto, N; Kondoh, Y; Hasegawa, Y

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Event date: 2019.10

    Language:English   Presentation type:Poster presentation  

    DOI: 10.1093/annonc/mdz343.108

  47. A PHASE II TRIAL OF ERLOTINIB FOR PREVIOUSLY TREATED JAPANESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS: RESULTS OF THE CENTRAL JAPAN LUNG STUDY GROUP TRIAL (CJLSG0904). International conference

    Hase, T; Morise, M; Taniguchi, H; Shindoh, J; Kojima, E; Tanikawa, Y; Suzuki, R; Ogasawara, T; Yamada, Y; Ando, M; Kondo, M; Saito, H; Hasegawa, Y

    JOURNAL OF THORACIC ONCOLOGY  2013.11 

     More details

    Event date: 2013.11

    Language:English   Presentation type:Poster presentation  

  48. PROGNOSTIC FACTORS IN RECURRENT SMALL-CELL LUNG CARCINOMA International conference

    Morise, M; Mizutani, T; Oguri, T; Imai, N; Hase, T; Shindo, Y; Inukai, Y; Ito, S; Hashimoto, N; Sato, M; Kondo, M; Hasegawa, Y

    ANNALS OF ONCOLOGY  2012.10 

     More details

    Event date: 2012.10

    Language:English   Presentation type:Poster presentation  

  49. Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC International coauthorship International conference

    Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

    ANNALS OF ONCOLOGY  2020.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  50. Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

    Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  51. Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status International conference

    Koyama Junji, Kimura Tomoki, Oi Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Matsuzawa Reiko, Fukihara Jun, Sakamoto Koji, Morise Masahiro, Hashimoto Naozumi, Kondoh Yasuhiro, Hasegawa Yoshinori

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

  52. Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen International conference

    Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2017.11 

     More details

    Language:English   Presentation type:Poster presentation  

  53. Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC). International conference

    Seto Takashi, Nishio Makoto, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Kim Young Hak, Azuma Koichi, Takiguchi Yuichi, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Tamura Tomohide

    JOURNAL OF CLINICAL ONCOLOGY  2019.5.20 

     More details

    Language:English   Presentation type:Poster presentation  

  54. eIF2 beta, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference

    Goto D., Tanaka I., Sato M., Kato T., Miyazawa A., Hase T., Morise M., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2018.10 

     More details

    Language:English   Presentation type:Poster presentation  

  55. Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung International conference

    Morise Masahiro, Hishida Tomoyuki, Takahashi Akiko, Yoshida Junji, Ohe Yuichiro, Nagai Kanji, Ishii Genichiro

    JOURNAL OF THORACIC ONCOLOGY  2017.1 

     More details

    Language:English   Presentation type:Poster presentation  

  56. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study International coauthorship International conference

    Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D. R., Jassem J.

    ANNALS OF ONCOLOGY  2019.12 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  57. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 International coauthorship International conference

    Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D., Jassem J.

    SWISS MEDICAL WEEKLY  2020.11.18 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  58. Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference

    Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  59. Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC International coauthorship International conference

    Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M. C., Stanton T. S., Morise M., Lee J-S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P. K.

    ANNALS OF ONCOLOGY  2020.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  60. A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan) International conference

    Daga Haruko, Umemura Shigeki, Ohe Yuichiro, Shiota Tetsuhiro, Fujita Masaki, Furuya Naoki, Tsuda Takeshi, Morise Masahiro, Matsumoto Shingo, Goto Koichi

    ANNALS OF ONCOLOGY  2017.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  61. Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT International conference

    Tamiya Y., Morise M., Matsuzawa R., Tanaka I., Okada T., Iwano S., Hase T., Hashimoto N., Sato M., Itoh Y., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

  62. Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer International conference

    Oi H., Yamano Y., Yokoyama T., Matsuda T., Morise M., Kataoka K., Kimura T., Kondoh Y.

    ANNALS OF ONCOLOGY  2019.11 

     More details

    Language:Japanese   Presentation type:Poster presentation  

  63. UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer International conference

    Goto D., Kizuki M., Uwatoko N., Kawai K., Koike M., Nakashima M., Miyazawa A., Tanaka I., Hase T., Morise M., Hasegawa Y., Minna J., Sato M.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  64. The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference

    Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE  2018.12 

     More details

    Presentation type:Poster presentation  

  65. Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A International coauthorship International conference

    Mazieres J., Paik P., Felip E., Veillon R., Sakai H., Cortot A., Viteri S., Garassino M., Van Meerbeeck J., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

    JOURNAL OF THORACIC ONCOLOGY  2021.1 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  66. Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data International coauthorship International conference

    Sakai H., Felip E., Cortot A. B., Veillon R., Griesinger F., Patel J., Horn L., Mazieres J., De Castro Carpeno J., Morise M., Sakamoto T., Bruns R., Scheele J., Straub J., Paik P.

    ANNALS OF ONCOLOGY  2018.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  67. Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A International coauthorship International conference

    Mazieres J., Paik P. K., Felip E., Veillon R., Sakai H., Cortot A. B., Viteri S., Garassino M. C., Van Meerbeeck J. P., Raskin J., Thomas M., Morise M., Cho B. C., Conte P., Bruns R., Demuth T., Schumacher K. M., Le X.

    ANNALS OF ONCOLOGY  2020.9 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  68. Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study International coauthorship International conference

    Sakai Hiroshi, Veillon Remi, Cortot Alexis B., Felip Enriqueta, Mazieres Julien, Morise Masahiro, Sakamoto Tomohiro, Tokito Takaaki, Atagi Shinji, Kato Terufumi, Kumagai Toru, Tanaka Hiroshi, Bruns Rolf, Straub Josef, Scheele Juergen, Le Xiuning, Paik Paul K.

    ANNALS OF ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  69. Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study International conference

    Park K., Felip E., Veillon R., Cortot A., Mazieres J., Sakai H., Reinmuth N., Viteri S., Chen Y-M., Han J-Y., Jang T-W., Morise M., Sakamoto T., Tokito T., Cho B. C., Bruns R., Scheele J., Straub J., Le X., Paik P. K.

    ANNALS OF ONCOLOGY  2019.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  70. Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping International coauthorship International conference

    Yang J. C-H., Le X., Cho B. C., Han J-Y., Morise M., Chen Y-M., Kang J-H., Kato T., Takeoka H., Chikamori K., Sakai H., Park K., Wu Y-L., Schumacher K., Bruns R., Straub J., Paik P.

    ANNALS OF ONCOLOGY  2020.11 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  71. Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC International coauthorship International conference

    Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M., Stanton T., Morise M., Lee J. -S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P.

    JOURNAL OF THORACIC ONCOLOGY  2021.1 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  72. Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy International conference

    Hase T., Miyazaki M., Ichikawa K., Yogo N., Ozawa N., Ando M., Morise M., Sato M., Kondo M., Yamada K., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2018.10 

     More details

    Language:English   Presentation type:Poster presentation  

  73. Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC International conference

    Matsuzawa R., Morise M., Tanaka I., Koyama J., Kimura T., Kondoh Y., Hase T., Sakamoto K., Hashimoto N., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY  2019.10 

     More details

    Language:English   Presentation type:Poster presentation  

  74. Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer International conference

    Fukihara J., Sakamoto K., Iwano S., Morise M., Hashimoto N., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2018 

     More details

    Language:English   Presentation type:Poster presentation  

  75. PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201). International conference

    Hase Tetsunari, Yanagisawa Kiyoshi, Fukatsu Asuki, Kimura Tomoki, Kojima Eiji, Abe Takashi, Imaizumi Kazuyoshi, Horio Yoshitsugu, Oguri Tetsuya, Yamamoto Masashi, Ogasawara Tomohiko, Sugino Yasuteru, Morise Masahiro, Nakatochi Masahiro, Ando Masahiko, Kondo Masashi, Saka Hideo, Saito Hiroshi, Hasegawa Yoshinori, Takahashi Takashi

    JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

     More details

    Language:English   Presentation type:Poster presentation  

  76. Phase II study of tepotinib in NSCLC patients with METex14 mutations. International coauthorship International conference

    Paik Paul K., Veillon Remi, Cortot Alexis B., Felip Enriqueta, Sakai Hiroshi, Mazieres Julien, Griesinger Frank, Horn Leora, Senellart Helene, Van Meerbeeck Jan P., de Castro Carpeno Javier, Patel Jyoti D., Garassino Marina Chiara, Morise Masahiro, Reinmuth Niels, Viteri Santiago, Tokito Takaaki, Sakamoto Tomohiro, Scheele Juergen, Le Xiuning

    JOURNAL OF CLINICAL ONCOLOGY  2019.5.20 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  77. Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). International conference

    Udagawa Hibiki, Ikeda Takaya, Umemura Shigeki, Daga Haruko, Toyozawa Ryo, Harada Daijiro, Sakakibara-Konishi Jun, Morise Masahiro, Yamamoto Noboru, Takahashi Toshiaki, Kato Terufumi, Shingyoji Masato, Ushio Ryota, Hara Satoshi, Takata Saori, Nomura Shogo, Matsumoto Shingo, Niho Seiji, Sato Akihiro, Goto Koichi

    JOURNAL OF CLINICAL ONCOLOGY  2020.5.20 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  78. Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study International conference

    Shimokawa M., Nosaki K., Seto T., Ohashi K., Morise M., Fujiwara Y., Sakakibara J., Murakami H., Yano S., Satouchi M., Matsumoto S., Goto K., Yoh K.

    ANNALS OF ONCOLOGY  2019.4 

     More details

    Language:English   Presentation type:Poster presentation  

  79. IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC International coauthorship International conference

    Herbst Roy, De Marinis Filippo, Giaccone Giuseppe, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos, Morise Masahiro, Font Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Mocci Simonetta, McCleland Mark, Enquist Ida, Komatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Spigel David

    JOURNAL FOR IMMUNOTHERAPY OF CANCER  2020.4 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  80. Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC International coauthorship International conference

    Reinmuth Niels, Spigel David, De Marinis Filippo, Giaccone Giuseppe, Verynenegre Alain, Barrios Carlos Henrique, Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozgueroglur Mustafa, Mocci Simonetta, Mccleland Mark, Enquist Ida, Kotnatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Herbst Roy S.

    ONCOLOGY RESEARCH AND TREATMENT  2020.2 

     More details

    Language:English   Presentation type:Oral presentation (general)  

  81. Impact Of Mild To Moderate COPD On Prognosis And Feasibility For Chemotherapy In Patients With Lung Cancer

    Omote N., Hashimoto N., Morise M., Miyazaki S., Ando A., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  2017 

     More details

    Presentation type:Oral presentation (general)  

  82. 2.著明な気管内病変を呈したmalignant fibrous histiocytoma(MFH)肺転移の1例(第41回 日本呼吸器内視鏡学会中部支部会)

    呂 成九, 岡地 祥太郎, 今井 直幸, 橋本 泉, 長谷 哲也, 進藤 有一郎, 森瀬 昌宏, 橋本 直純, 佐藤 光夫, 近藤 征史, 今泉 和良, 長谷川 好規

    気管支学  2011  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.33.5_378_2

    CiNii Research

  83. 21-7-O14-08 高齢者肺癌カルボプラチン併用療法における悪心・嘔吐のリスク因子の検討(がん薬物療法(副作用対策),口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

    市川 和哉, 森瀬 昌宏, 宮崎 雅之, 亀島 理沙, 長谷 哲成, 近藤 征史, 長谷川 好規, 山田 清文

    日本医療薬学会年会講演要旨集  2015.10.23  一般社団法人 日本医療薬学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.20825/amjsphcs.25.0_209_3

    CiNii Research

  84. 6.EBUS-TBNAが診断に有用であったHodgkinリンパ腫の1例(第39回 日本呼吸器内視鏡学会中部支部会)

    飛田 理世, 小栗 知世, 森瀬 昌宏, 今井 直幸, 橋本 泉, 橋本 直純, 佐藤 光男, 近藤 征史, 今泉 和良, 長谷川 好規

    気管支学  2010  特定非営利活動法人 日本呼吸器内視鏡学会

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    DOI: 10.18907/jjsre.32.5_477_6

    CiNii Research

▼display all

Research Project for Joint Research, Competitive Funding, etc. 9

  1. Phase II study of docetaxel plus ramucirumab after treatment of platinum based chemotherapy combined with immune check point inhibitors in patients with non-small cell lung cancer

    2019.11

  2. 進行肺癌の血漿遊離DNAを利用したマルチ遺伝子解析法に基づく個別化医療の確立を目指した研究(AMED)

    2019.4 - 2022.3

    革新的がん医療実用化研究事業  

      More details

    Grant type:Competitive

  3. 希少遺伝子変異を有する小細胞肺癌に対する新規治療法の確立に関する研究 (AMED)

    2019.4 - 2020.3

    革新的がん医療実用化研究事業 

      More details

    Grant type:Competitive

  4. ROS1融合遺伝子陽性の進行固形がんに対する治療開発を目指した研究 (AMED)

    2018.10 - 2021.3

    革新的がん医療実用化研究事業 

      More details

    Grant type:Competitive

  5. RET肺がんに対するアレクチニブの医師主導治験と耐性機構解析 (AMED)

    2018.4 - 2020.3

    革新的がん医療実用化研究事業 

      More details

    Grant type:Competitive

  6. 次世代シークエンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

    2018 - 2019

    革新的がん医療実用化研究事業  

    岡本勇

      More details

    Grant type:Competitive

  7. 悪性胸膜中皮腫に対する血管新生阻害剤の効果予測モデル構築に基づく新治療法確立に関する研究 (AMED)

    2017.9 - 2018.3

    革新的がん医療実用化研究事業 

    長谷川好規

      More details

    Grant type:Competitive

  8. 遺伝子スクリーニング基盤(LC-SCRUM-Japan)を利用した、MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究 (AMED)

    2017.4 - 2020.3

    革新的がん医療実用化研究事業  

      More details

    Grant type:Competitive

  9. Efficacy and safety of oral granisetron and dexamethasone for crizotinib-induced nausea and vomiting in patient with non-small cell lung cancer (NSCLC)

    2015.1

    Cooperative Research within Japan 

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 6

  1. 高齢進行肺癌患者における、VES-13ならびにMMSEの有用性に関する検討

    2013.4 - 2016.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Coinvestigator(s) 

  2. 肺神経内分泌腫瘍に対する腫瘍血管新生を標的とした治療の低侵襲効果予測法の確立

    Grant number:23K06908  2023.4 - 2027.3

    科学研究費助成事業  基盤研究(C)

    森瀬 昌宏, 菊地 良介, 木下 文恵

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    肺神経内分泌腫瘍は、神経内分泌学的特性を有する悪性腫瘍で、Vascular Endothelial Growth Factor(VEGF)-Aが新規治療標的として注目され、抗VEGF-A抗体の臨床開発が進んでいる。本研究は、肺神経内分泌腫瘍の細胞株を用いた解析をもとにAIによる機械学習アルゴリズムを活用し、VEGF-A機能解析に基づく腫瘍血管新生治療の効果予測モデルを確立し、低侵襲な臨床検査法の構築をめざす。

  3. 悪性中皮腫におけるオキシトシン受容体を標的とした新規治療法の開発

    Grant number:20H03689  2020.4 - 2023.3

    科学研究費助成事業  基盤研究(B)

    田中 一大, 関戸 好孝, 森瀬 昌宏, 佐藤 光夫, 松原 大祐

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    悪性中皮腫は希少な腫瘍であるが極めて予後不良であり、新規治療法の開発が切望されている。研究代表者はこれまでの解析で、約40%の悪性中皮腫において著しく高発現している受容体に着眼し、独立した予後予測因子であることを発見した。さらにin vitro の解析で、同遺伝子をノックダウンすると、中皮腫細胞株の増殖が有意に抑制されることを見出した。これらの結果を基軸に、本研究では1)悪性中皮腫における同受容体下流の細胞内シグナル経路の解明、2)同受容体阻害剤の抗腫瘍効果の検証、3)さらに悪性中皮腫の組織検体を用いて免疫染色を施行し、同受容体を標的とした治療対象を選出するプロトコルの最適化を行う。
    2020年度の解析で、中皮腫細胞に対してレンチウィルスを用いてオキシトシン受容体をノックダウンすると、細胞周期G1期停止を誘導し、mRNAレベルでcyclin dependent kinase やAurora kinase Aなど複数の細胞周期制御因子の発現が低下していることを突き止めていた。2021年度は、オキシトシン受容体を高発現する2種類の中皮腫細胞株を用いて、同受容体をノックダウンした後に、LC-MS分析を施行し、網羅的なタンパク質の発現変動を解析した。その結果、タンパク質レベルでも複数の細胞周期制御因子の発現低下が確認され、2020年度と一致した知見が得られた。また、LC-MS分析の解析結果から、変化率が大きく細胞周期制御に関連する分子を選択し、オキシトシン刺激・同受容体をノックダウンした場合との発現変化の一致について検証を行った。さらに、選択した候補分子に対する核酸・阻害剤を用いて、中皮腫細胞株に対する増殖抑制効果を解析し、オキシトシン受容体の下流に位置する因子の絞り込みを行った。その中で、悪性中皮腫の増殖に影響し、同因子に対する阻害剤を用いた場合の抗腫瘍効果がより強い標的因子を発見した。
    また、TCGAのデータベースを用いたオキシトシン受容体の発現と予後との解析については、組織型やステージを加えた多変量解析を行い、同受容体の発現が高いほど予後が悪く、独立した予後予測因子になりうることを同定した。これらの解析結果を、日本癌学会の機関誌であるCancer Scienceに報告した(Cancer Sci . 2021 Sep;112:3520-3532.)。さらに2021年10月に、オキシトシン受容体阻害剤を用いた治療法を悪性中皮腫に対する新規の抗腫瘍療法として、特許取得のためのPCT出願を行った(出願番号:2020-180412)。
    2020年度までの解析で、悪性中皮腫細胞株に対してオキシトシン受容体をノックダウンした際の細胞増殖抑制のメカニズムについて、cyclin dependent kinase 1やAurora kinase Aなど複数の細胞周期制御因子の発現が低下に基づく細胞周期停止である可能性を突き止めていた。2021年度の解析では、オキシトシン受容体をノックダウンした後に、LC-MSを用いたプロテオーム解析・リン酸化プロテオーム解析を施行することで得た網羅的なタンパク質の発現変動解析においても、2020年度と一致した見解が得られた。悪性中皮腫において、オキシトシン-オキシトシン受容体のシグナル経路が細胞周期を制御し、腫瘍増殖に影響を及ぼしていることが確認された。また、下流シグナル分子を同定する上で、LC-MS分析を行い有望と考えられる分子を複数得たことから、当初の予定通り、オキシトシン刺激・同受容体をノックダウンした場合の発現変化が一致しているかどうかについても検証を行った。候補分子の中で、阻害剤が購入可能なものについては、中皮腫細胞株に対する増殖抑制効果についてIC-50等で検討を重ね、よりIC-50が低く有望と考えられる標的分子についても同定した。一方で、新型コロナの流行により入手不可能となった阻害剤・資材もあり、当初の計画よりやや遅れが生じた。
    TCGAのデータベースを用いた予後解析については、オキシトシン受容体の発現が予後に影響し、独立した予後予測因子になりうることを同定した。しかし、オキシトシン受容体の発現を免疫染色で検出するため、複数の抗体を用いて検討を行ったが、有効な抗体は確認できなかった。オキシトシン受容体の発現レベルを予後予測因子として臨床応用する上では、さらなる検討が必要と考えられた。
    LC-MS分析の解析結果から絞り込みを行った、オキシトシン受容体の下流の候補分子については、細胞増殖抑制メカニズム・阻害剤を用いた抗腫瘍効果についてさらに詳細な解析を行う。具体的には、レンチウィルスを用いて同因子を恒常的にノックダウンした後に、細胞周期解析を施行することで、オキシトシン受容体をノックダウンした場合との一致率について検証する。また、同因子に対する阻害剤においては、複数の中皮腫細胞株・不死化した正常中皮の細胞株を用いて追加検討を行う。同因子の発現レベルだけでなくオキシトシン受容体の発現レベルも含めて多角的な視点で検討を行うことで、悪性中皮腫に対してより広範に使用できかつ抗腫瘍効果の高い阻害剤の選出を行う。有望な阻害剤については、殺細胞性の抗がん剤との併用効果及び、in vivoでの抗腫瘍効果を解析する。
    また、同定された下流因子については、TCGAのデータベースを用いて、予後への影響やオキシトシン受容体の発現との関連について解析する。さらに、名古屋大学が保持する悪性中皮腫の組織検体を用いて免疫染色で同因子を検出するためのプロトコルの確立を目指し、最終的には免疫染色の結果と臨床情報を統合することで、患者背景・抗がん剤の効果・予後との関連について解析を行う。オキシトシン受容体の免疫染色については、受注委託でカスタム抗体を作成し、さらなる追加の検討を行う。

  4. 呼吸器悪性腫瘍における血管新生阻害治療の低侵襲な効果予測法を確立をめざす研究

    Grant number:19K07910  2019.4 - 2023.3

    森瀬 昌宏

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    呼吸器悪性腫瘍(肺癌・悪性胸膜中皮腫・胸腺腫瘍)は、いずれも予後が不良の疾患です。これらの腫瘍の増殖、転移には腫瘍内の血管新生が大きく関与しているため、血管新生阻害治療が重要な治療法の一つとして注目されています。しかし、血管新生阻害治療が有効な患者さんを事前に判定する効果予測法は確立されていません。本研究は、血管新生の過程に重要な蛋白であるVEGF-Aに着目して、体に負担の少ない方法での血管新生阻害剤の効果を予測する方法を確立することを目指します。
    悪性胸膜中皮腫の症例に関して、患者背景、標準治療であるシスプラチン・ペメトレキセド、ニボルマブの各治療効果を含む臨床データを集積した。胸膜剥皮、胸膜肺全摘術を含む外科治療との集学的治療症例に関しても各治療効果を含む臨床データの集積を完了した。悪性胸膜中皮腫においては、腫瘍volumeと腫瘍から産生されるVEGF-A量の相関が存在する可能性を想定しており、volume softwareを用いた腫瘍量測定の実施を完了した。今後、VEGF-A発現との相関について解析を実施していく予定である。肺癌症例に関しては、血管新生促進型VEGF-A165a/抑制型VEGF-A165b産生能のheterogeneity評価として進行肺癌症例におけるVEGF-A165a/VEGF-A165bバランスを血漿Total VEGF-A, VEGF-A165bを同時に評価する方法で解析を実施した。解析の結果、個々の症例ごとにVEGF-A165a/VEGF-A165bバランスにはheterogeneityが存在することが確認された。現在、進行肺癌において血管新生阻害剤は、初回治療、二次治療両者で実用化されている。すなわち初回治療において抗VEGF-A抗体のベバシズマブは、従来から実用化されていたEGFRチロシンキナーゼ阻害剤、プラチナ併用化学療法との併用に加えて、免疫療法と血管新生阻害剤の併用療法の有効性が注目されており、今後、これらの治療をうける患者の治療前血漿にてVEGF-A165a/VEGF-A165bバランスの評価を行っていく予定である。また既治療例においてもVEGFR-2受容体阻害剤が殺細胞性抗がん剤であるドセタキセルとの併用で生存延長効果を示しており、これらの薬剤に関する効果予測手法についても検討を継続していく計画である。
    胸膜中皮腫の臨床コホート集積を完了した。肺癌症例ではVEGF-A165a/VEGF-A165bバランスにはheterogeneityが存在することから血管新生阻害剤治療群と非治療群を集積し、効果予測因子、予後予測因子の判別解析で血管新生阻害治療の効果予測法の確立について検討をすすめていく方針である。
    肺癌症例において血管新生阻害剤治療群と非治療群を集積し、効果予測因子、予後予測因子の判別解析で血管新生阻害治療の効果予測法の確立について検討をすすめていく方針である。

  5. Fundamental research for treatment optimization in elderly patients with mesothelioma

    Grant number:15K08905  2015.4 - 2018.3

    MASAHIRO MORISE

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    Chemotherapy induced nausea and vomitting (CINV) can be associated with discontinuation of cisplatin plus pemetrexed/carboplatin plus pemetrexed, which are standard regimen for advanced malignant mesothelioma. Based on our research, pemetrexed regimen showed higer indcidence of CINV compared to non-pemetrexed 3rd generation anticancer drugs.

  6. An observational study for evaluating predictability of the Vulnerable Elders Survey (VES) -13 for cognitive impairment in elderly patients with advanced cancer

    Grant number:25460896  2013.4 - 2017.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Ando Masahiko

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    We examined an association between treatment outcomes and Vulnerable Elders Survey-13 (VES-13), Mini-Mental State Examination (MMSE), and Charlson Comorbidity Index (CCI) in 101 patients aged 65 years or older with advanced non-small cell lung cancer who received carboplatin and pemetrexed as a first-line chemotherapy. In the Cox proportion hazards model including age, sex, disease stage, and performance status as covariates, VES-13 showed significant association with overall survival. Performance status, VES-13, and CCI had a significant association with progression-free survival. In the logistic regression analysis, performance status, MMSE, and CCI demonstrated a significant association with antitumor response. Age was not significantly correlated with any treatment outcome. These results suggest the importance of geriatric assessment in predicting treatment outcomes in elderly patients in advanced non-small cell lung cancer receiving a standard combination chemotherapy.

▼display all

 

Social Contribution 1

  1. 医療従事者に知ってほしい肺がん医療 講演「医療従事者に知ってほしい肺がんの最新治療」

    2015.8